Gynae oncologyFree in the app
Endometrial cancer
FIGO 2023 — histology and molecular type now change the stage.
Source: FIGO 2023Stage I–II
| IA1 | Non-aggressive, limited to polyp or endometrium. |
|---|---|
| IA2 | Non-aggressive, <50% myometrium, no/focal LVSI. |
| IA3 | Low-grade endometrioid in uterus + ovary. |
| IB | Non-aggressive, ≥50% myometrium. |
| IC | Aggressive type limited to polyp/endometrium. |
| IIA | Cervical stroma (non-aggressive). |
| IIB | Substantial LVSI (non-aggressive). |
| IIC | Aggressive type with any myometrial invasion. |
Stage III–IV
| IIIA1 | Ovary or tube. |
|---|---|
| IIIA2 | Uterine serosa. |
| IIIB1 | Vagina or parametrium. |
| IIIB2 | Pelvic peritoneum. |
| IIIC1 | Pelvic nodes. |
| IIIC2 | Para-aortic nodes to renal vessels. |
| IVA | Bladder/bowel mucosa. |
| IVB | Abdominal peritoneum beyond pelvis. |
| IVC | Distant (lung, liver, brain, bone, distant nodes). |
Molecular
| POLEmut | Stage I–II → IAm (better prognosis). |
|---|---|
| p53abn | Stage I–II with myometrial invasion → IICm. |
| MMRd / NSMP | No change to stage. |
A summary for trained clinicians. Always check the full guideline, the patient in front of you and your hospital's protocol. Spotted an error? Tell us.